Windward Bio
Windward Bio is a clinical-stage drug development company focused on improving outcomes for patients with advanced immunological diseases, initially targeting severe respiratory conditions. Their lead candidate, WIN378, is a long-acting monoclonal antibody aiming to reduce treatment burden, and they are also developing a pipeline of long-acting bispecifics.
Buy Funded Startups lists
Funding Round: Series A
Funding Amount: $200M
Date: 10-Jan-2025
Investors: OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, Pivotal bioVenture Partners
Markets: Biotechnology, Pharmaceuticals, Immunology, Life Science, Medical
HQ: Basel, Basel-Stadt, Switzerland
Founded: 2024
Website: https://www.windwardbio.com/
LinkedIn: https://www.linkedin.com/company/windward-bio-001
Crunchbase: https://www.crunchbase.com/organization/windward-bio
Leave a Comment
Comments
No comments yet.